Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Oct 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a specific type of test, called pH-impedance (pH-MII), can help classify a condition known as gastroesophageal reflux disease (GERD). GERD happens when stomach acid frequently flows back into the tube connecting your mouth and stomach, which can cause symptoms like heartburn. Researchers want to see if the results from this test, when analyzed correctly, can improve the way doctors understand and classify GERD based on new guidelines.

To be part of this study, participants must be adults aged 18 to 80 who have undergone a pH-MII test using Medtronic equipment. People who have had certain types of stomach or esophagus surgeries, or who have had previous tests showing significant structural issues, are not eligible. If you join this trial, you'll be helping researchers gather important information that could lead to better diagnosis and treatment options for GERD in the future. The trial is currently recruiting participants, so it's a great opportunity to contribute to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients aged 18 - 80 years old;
• • pH-MII performed off PPI
• Exclusion Criteria:
• • Prior upper GI endoscopy indicative of structural disease (except for oesophagitis or hiatal hernia).
• • Incomplete pH-MII (less than 21 hours recording);
• • Ph-MII performed on PPI
• • Suboptimal quality of the tracings preventing interpretation in clinical practice;
• • Prior oesophageal (including anti-reflux intervention) or gastric surgery.